Literature DB >> 24216022

Decoding the complexity of type I interferon to treat persistent viral infections.

Elizabeth B Wilson1, David G Brooks.   

Abstract

Type I interferons (IFN-I) are a broad family of cytokines that are central to the innate immune response. These proteins have long been appreciated for the critical roles they play in restraining viral infections and shaping antiviral immune responses. However, in recent years there has been increased awareness of the immunosuppressive actions of these proteins as well. Although there are many current therapeutic applications to manipulate IFN-I pathways, we have limited understanding of the mechanisms by which these therapies are actually functioning. In this review, we highlight the diversity and temporal impact of IFN-I signaling, discuss the current therapeutic uses of IFN-I, and explore the strategy of blocking IFN-I to alleviate immune dysfunction in persistent virus infections.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  HIV; LCMV; immune activation; immunosuppression; persistent; therapy; type I interferon; virus

Mesh:

Substances:

Year:  2013        PMID: 24216022      PMCID: PMC3864553          DOI: 10.1016/j.tim.2013.10.003

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN: 0966-842X            Impact factor:   17.079


  72 in total

Review 1.  Type I interferons in host defense.

Authors:  Daniel B Stetson; Ruslan Medzhitov
Journal:  Immunity       Date:  2006-09       Impact factor: 31.745

Review 2.  Gene expression profiling in human autoimmunity.

Authors:  Emily C Baechler; Franak M Batliwalla; Ann M Reed; Erik J Peterson; Patrick M Gaffney; Kathy L Moser; Peter K Gregersen; Timothy W Behrens
Journal:  Immunol Rev       Date:  2006-04       Impact factor: 12.988

3.  Systematic identification of type I and type II interferon-induced antiviral factors.

Authors:  Su-Yang Liu; David Jesse Sanchez; Roghiyh Aliyari; Sun Lu; Genhong Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-27       Impact factor: 11.205

4.  Interferon action in triply deficient mice reveals the existence of alternative antiviral pathways.

Authors:  A Zhou; J M Paranjape; S D Der; B R Williams; R H Silverman
Journal:  Virology       Date:  1999-06-05       Impact factor: 3.616

5.  Evolving expectations around early management of multiple sclerosis.

Authors:  Ralf Gold; Jerry S Wolinsky; Maria Pia Amato; Giancarlo Comi
Journal:  Ther Adv Neurol Disord       Date:  2010-11       Impact factor: 6.570

6.  Reduction of immune activation with chloroquine therapy during chronic HIV infection.

Authors:  Shannon M Murray; Carrie M Down; David R Boulware; William M Stauffer; Winston P Cavert; Timothy W Schacker; Jason M Brenchley; Daniel C Douek
Journal:  J Virol       Date:  2010-09-15       Impact factor: 5.103

7.  Blockade of chronic type I interferon signaling to control persistent LCMV infection.

Authors:  Elizabeth B Wilson; Douglas H Yamada; Heidi Elsaesser; Jonathan Herskovitz; Jane Deng; Genhong Cheng; Bruce J Aronow; Christopher L Karp; David G Brooks
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

8.  Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response.

Authors:  Béatrice Jacquelin; Véronique Mayau; Brice Targat; Anne-Sophie Liovat; Désirée Kunkel; Gaël Petitjean; Marie-Agnès Dillies; Pierre Roques; Cécile Butor; Guido Silvestri; Luis D Giavedoni; Pierre Lebon; Françoise Barré-Sinoussi; Arndt Benecke; Michaela C Müller-Trutwin
Journal:  J Clin Invest       Date:  2009-12       Impact factor: 14.808

Review 9.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

Authors:  J E Darnell; I M Kerr; G R Stark
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

Review 10.  IFN-α in the treatment of melanoma.

Authors:  Ahmad A Tarhini; Helen Gogas; John M Kirkwood
Journal:  J Immunol       Date:  2012-10-15       Impact factor: 5.422

View more
  17 in total

1.  Bacterial expression and preliminary crystallographic studies of a 149-residue fragment of human Caprin-1.

Authors:  Yuhong Wu; Jiang Zhu; Xiaolan Huang; Zhihua Du
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2015-02-19       Impact factor: 1.056

2.  The unique immunological and microbial aspects of pregnancy.

Authors:  Gil Mor; Paulomi Aldo; Ayesha B Alvero
Journal:  Nat Rev Immunol       Date:  2017-06-19       Impact factor: 53.106

3.  Sex Differences in Plasmacytoid Dendritic Cell Levels of IRF5 Drive Higher IFN-α Production in Women.

Authors:  Morgane Griesbeck; Susanne Ziegler; Sophie Laffont; Nikaïa Smith; Lise Chauveau; Phillip Tomezsko; Armon Sharei; Georgio Kourjian; Filippos Porichis; Meghan Hart; Christine D Palmer; Michael Sirignano; Claudia Beisel; Heike Hildebrandt; Claire Cénac; Alexandra-Chloé Villani; Thomas J Diefenbach; Sylvie Le Gall; Olivier Schwartz; Jean-Philippe Herbeuval; Brigitte Autran; Jean-Charles Guéry; J Judy Chang; Marcus Altfeld
Journal:  J Immunol       Date:  2015-10-30       Impact factor: 5.422

Review 4.  The immunological, environmental, and phylogenetic perpetrators of metastatic leishmaniasis.

Authors:  Mary-Anne Hartley; Stefan Drexler; Catherine Ronet; Stephen M Beverley; Nicolas Fasel
Journal:  Trends Parasitol       Date:  2014-06-20

5.  Epigenetic manipulation restores functions of defective CD8⁺ T cells from chronic viral infection.

Authors:  Fuqin Zhang; Xiaohui Zhou; Joanna R DiSpirito; Chuan Wang; Ying Wang; Hao Shen
Journal:  Mol Ther       Date:  2014-05-27       Impact factor: 11.454

6.  Type I interferon suppresses de novo virus-specific CD4 Th1 immunity during an established persistent viral infection.

Authors:  Ivan Osokine; Laura M Snell; Cameron R Cunningham; Douglas H Yamada; Elizabeth B Wilson; Heidi J Elsaesser; Juan Carlos de la Torre; David Brooks
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-05       Impact factor: 11.205

7.  Human pDCs preferentially sense enveloped hepatitis A virions.

Authors:  Zongdi Feng; You Li; Kevin L McKnight; Lucinda Hensley; Robert E Lanford; Christopher M Walker; Stanley M Lemon
Journal:  J Clin Invest       Date:  2014-11-21       Impact factor: 14.808

8.  Targeting type I interferon-mediated activation restores immune function in chronic HIV infection.

Authors:  Anjie Zhen; Valerie Rezek; Cindy Youn; Brianna Lam; Nelson Chang; Jonathan Rick; Mayra Carrillo; Heather Martin; Saro Kasparian; Philip Syed; Nicholas Rice; David G Brooks; Scott G Kitchen
Journal:  J Clin Invest       Date:  2016-12-12       Impact factor: 14.808

Review 9.  The role of type I interferons in intestinal infection, homeostasis, and inflammation.

Authors:  Hyeseon Cho; Brian L Kelsall
Journal:  Immunol Rev       Date:  2014-07       Impact factor: 12.988

10.  Improvements and Limitations of Humanized Mouse Models for HIV Research: NIH/NIAID "Meet the Experts" 2015 Workshop Summary.

Authors:  Ramesh Akkina; Atef Allam; Alejandro B Balazs; Joel N Blankson; John C Burnett; Sofia Casares; J Victor Garcia; Kim J Hasenkrug; Fatah Kashanchi; Scott G Kitchen; Florian Klein; Priti Kumar; Andrew D Luster; Larisa Y Poluektova; Mangala Rao; Brigitte E Sanders-Beer; Leonard D Shultz; Jerome A Zack
Journal:  AIDS Res Hum Retroviruses       Date:  2016-02       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.